Welcome!

News Feed Item

Vaccine Industry Watchdog Responds to Forbes' Defense of Mercury-Laced Vaccinations

Dr. Brian Hooker, PhD, says Forbes misrepresented congressional record and CDC studies

CHARLOTTE, N.C., Feb. 28, 2014 /PRNewswire-iReach/ -- Last week, PhD biochemist Brian Hooker created a stir when he announced he had obtained sensitive documents from the CDC (Centers for Disease Control and Prevention) through Freedom of Information Act (FOIA) requests. According to Hooker, these documents implicated the vaccine preservative Thimerosal (50% mercury by weight) in causing autism and other neurodevelopmental disorders, revealing what he says CDC officials had long known, but never disclosed publicly: a 7.6-fold increase in autism during infancy after exposure. Emily Willingham, who frequently editorializes in support of the vaccine program, responded in Forbes by criticizing a news story that went viral on the subject of Dr. Hooker's FOIA revelations.

(Photo: http://photos.prnewswire.com/prnh/20140228/MN73622)

Dr. Hooker methodically itemized "misrepresentations and outright errors" that he says appeared in Forbes.com. "Willingham either confused two CDC studies or intentionally deceived Forbes' readers," said Hooker. "There was one concealed study that found a very high association between Thimerosal and autism. That was the study that was kept from the public which I obtained. And there was a later study by the same researcher – CDC-paid epidemiologist Thomas Verstraeten – who had watered down the results of the earlier study to appear as if there were no association between Thimerosal and autism. That second study was made public even though it was fraudulent.  Willingham pointed to the conclusions of the later study and implied that they came from the earlier study."

Although Willingham denies that the CDC researcher, Dr. Verstraeten, was under pressure to alter the results of the earlier study, Dr. Hooker points out that Verstraeten's own email written at the time (an internal CDC document obtained through FOIA) reveals otherwise. Verstraeten's subject line, "It just won't go away," refers to his difficulty in making the statistical association between Thimerosal and autism disappear.

Making an example of how he says Dr. Verstraeten hid that association in his reanalysis of the data on 400,000 infants, Dr. Hooker says Verstraeten did not include clinics within HMOs where there was a strong correlation between Thimerosal exposure and autism incidence. According to Hooker, "Willingham brazenly disregarded Verstraeten's own chilling words: 'All the harm is done in the first month [of life]…' He wrote those words about the study I obtained."  The abstracts of Verstraeten's two studies and further comment on the controversy can be viewed here.

Dr. Hooker says Willingham misrepresented the congressional record when she selected quotes from a 2007 U.S. Senate report which falsely asserted that allegations of a cover-up are unsubstantiated. He considers the U.S. House of Representatives' 2003 report titled Mercury in Medicine (the result of a 3-year investigation) a "scathing, 80-page indictment of the CDC regarding the Thimerosal coverup."  The report concludes, "Our public health agencies' failure to act is indicative of institutional malfeasance for self-protection and misplaced protectionism of the pharmaceutical industry."

Willingham treated Verstraeten's final, watered-down results as solid epidemiological evidence, when, according to Hooker, the final version of the Verstraeten study is fraught with statistical flaws, primarily "overmatching." He provided an example:  the cases and controls received the same vaccination schedule and the same Thimerosal dosage; thus, no true comparison could be made.  Hooker says this invalidates all of the analyses (done separately for HMOs A, B and C).

Willingham quoted Verstraeten's  2004 letter in the journal Pediatrics regarding his later, diluted study, omitting the fact that the CDC has used the study to exonerate Thimerosal despite Verstraeten calling the study "neutral."  In addition, the 2004 Institute of Medicine (IOM) Immunization Safety Review (ISR) committee report used this as the only U.S. epidemiological study (among the 5 studies) as the basis to reject the Thimerosal-autism hypothesis, shutting the door on any further research. 

"In light of Ms. Willingham's enthusiastic defense of mercury in vaccines despite conclusive evidence of its harm to children, it is ironic that the tagline for her column is 'I write about the science they are selling you.'" remarked Dr. Hooker. Thimerosal is still administered to pregnant women and infants via the flu shot.

Brian Hooker, PhD, PE is an associate professor of biology at Simpson University. His over 50 science and engineering papers have been published in internationally recognized, peer-reviewed journals. He has a son, aged 16, who developed normally but then regressed into autism after receiving Thimerosal-containing vaccines. Dr. Brian Hooker's investigative research is sponsored by the Focus Autism Foundation, which is dedicated to informing the public about the cause(s) of the autism epidemic and the rise of chronic illnesses. To learn more, visit focusautisminc.org and ashotoftruth.org,  an educational website sponsored by Focus Autism. 

AutismOne is co-sponsoring this message and is a non-profit 501(c)(3) organization that provides education and supports advocacy efforts for children and families touched by an autism diagnosis. To learn more, visit autismone.org.

Media Contact: Angela Medlin, A Shot of Truth, 1 866-498-2768, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Brian Hooker, PhD, PE

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Twistlock, the leading provider of cloud container security solutions, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Twistlock is the industry's first enterprise security suite for container security. Twistlock's technology addresses risks on the host and within the application of the container, enabling enterprises to consistently enforce security policies, monitor...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus intern...
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to ov...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The 21st International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive ad...
This talk centers around how to automate best practices in a multi-/hybrid-cloud world based on our work with customers like GE, Discovery Communications and Fannie Mae. Today’s enterprises are reaping the benefits of cloud computing, but also discovering many risks and challenges. In the age of DevOps and the decentralization of IT, it’s easy to over-provision resources, forget that instances are running, or unintentionally expose vulnerabilities.
Everywhere we turn in our industry we can find strong opinions about the direction, type and nature of cloud’s impact on computing and business. Another word that is used in every context in our industry is “hybrid.” In his session at 20th Cloud Expo, Alvaro Gonzalez, Director of Technical, Partner and Field Marketing at Peak 10, will use a combination of a few conceptual props and some research recently commissioned by Peak 10 to offer a real-world consideration of how the various categories of...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
When NSA's digital armory was leaked, it was only a matter of time before the code was morphed into a ransom seeking worm. This talk, designed for C-level attendees, demonstrates a Live Hack of a virtual environment to show the ease in which any average user can leverage these tools and infiltrate their network environment. This session will include an overview of the Shadbrokers NSA leak situation.
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...